SCHEMBL4901634

SCHEMBL4901634

CC(O)C[N+]1(C)CCCC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 3/20 0.46
APOBEC3G Q9HC16 3/20 0.46
PABPC1 P11940 2/20 0.46
EIF4H Q15056 1/20 0.46
TP53 P04637 1/20 0.37
KDM4E B2RXH2 2/20 0.36
TSHR P16473 4/20 0.36
TDP1 Q9NUW8 2/20 0.36
CYP3A4 P08684 1/20 0.36
LMNA P02545 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36
BBOX1 O75936 2/20 0.35
SLC22A2 O15244 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.31
ALDH1A1 P00352 1/20 0.30
SLC18A3 Q16572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4901033 0.97 APOBEC3A (0.48) APOBEC3AAPOBEC3GPABPC1EIF4HTP53
Water SCHEMBL1356208 0.97 APOBEC3A (0.44) APOBEC3AAPOBEC3GPABPC1EIF4HTP53
SCHEMBL4904797 0.89 PABPC1 (0.35) APOBEC3AAPOBEC3GPABPC1EIF4HTSHR
Acetic Acid SCHEMBL9056408 0.85 LMNA (0.44) APOBEC3AAPOBEC3GPABPC1EIF4HTP53
SCHEMBL4903057 0.82 PABPC1 (0.32) APOBEC3AAPOBEC3GPABPC1EIF4HTSHR
SCHEMBL4893769 0.80 PABPC1 (0.32) APOBEC3AAPOBEC3GPABPC1EIF4H
SCHEMBL4899509 0.78 APOBEC3A (0.43) APOBEC3AAPOBEC3GPABPC1EIF4HCTDSP1
SCHEMBL4893851 0.78 PABPC1 (0.31) APOBEC3AAPOBEC3GPABPC1EIF4H
SCHEMBL3763848 0.78 APOBEC3A (0.39) APOBEC3AAPOBEC3GPABPC1EIF4HTP53
SCHEMBL4903132 0.77 PABPC1 (0.30) APOBEC3AAPOBEC3GPABPC1EIF4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150297718-A1 IONTOPHORESIS DELIVERY OF CATIONIC PRODRUGS FOR TOPICAL TREATMENT OF MUSCULOSKELETAL OR SKIN DISEASES YAN GUANG (US) 2015-10-22 US disclosed
EP-1867667-B1 Method for manufacturing stabilized polyacetal resin POLYPLASTICS CO (JP) 2012-10-31 EP disclosed
US-20080271381-A1 Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin POLYPLASTICS CO., LTD (JP) 2008-11-06 US disclosed
EP-1867667-A1 Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin Polyplastics Co., Ltd. (JP) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297718-A1 IONTOPHORESIS DELIVERY OF CATIONIC PRODRUGS FOR TOPICAL TREATMENT OF MUSCULOSKELETAL OR SKIN DISEASES TNNC1, MUSK, MMP1 APOBEC3A 2108/4885APOBEC3G 1647/4885PABPC1 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.